Safety and Immunogenicity Study of the Malaria Vaccines FP9 PP and MVA PP

NCT00374998 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Malaria, Falciparum
Malaria

Interventions

BIOLOGICAL: FP9-PP (FP9 polyprotein)
BIOLOGICAL: MVA-PP (Modified Virus Ankara polyprotein)

Sponsor

European Vaccine Initiative

Collaborators

[object Object]
[object Object]